Biomarkers
bringing the right patient
to the right care

About us

BrainDTech focuses on the early detection and monitoring of neurological and neurodegenerative diseases in liquid biopsies, based on miRNA from microglial microvesicles.
Meet our team
Image

Our technology

Before a neurodegenerative disease can be treated, it needs to be detected. Today, in most brain diseases, diagnosis relies largely on observing clinical symptoms, which occur when the neurodegeneration has already caused irreversible damages.

Image

The earlier, the better

BrainDTech has discovered and patented a method for diagnosis, prognosis and treatment monitoring of neurodegenerative, neurological and inflammatory diseases based on miRNA inside microglia microvesicles, a new molecular mechanism which occurs in the very early stages of neuroinflammation.

more

The approach

Inflamed microglia release microvesicles, which can be collected from liquid biopsies. These microvesicle contain miRNAs, and the miRNA content changes inside microvesicles depending on the disease: there is a specific miRNA signature for each pathology.
The comprehension of these patterns enables unprecedent level of comprehension of brain disease scenarios.

Image

Liquid biopsy
retrieval

Image

Microglia MV
Isolation

Image

RNA
extraction

Image

miRNA
sequencing

Image

Pathology specific miRNA panel development

Main applications

Early diagnosis

Biomarkers that predict brain diseases prior to symptoms

Treatment monitoring

Biomarkers that quantitatively evaluate therapy efficacy

Disease staging

Biomarkers for patient group clustering for clinical studies

Target identification

Biomarkers for downstream ID of novel drug targets

Image

Our pipeline

BrainDTech is running several clinical studies, either directly sponsored or in partnership with leading international Key Opinion Leaders and pre-competitive consortia.

Latest news

2024

  • Best Neurological & Neurodegenerative Disease Detection Company 2024 – Southern Europe Award [GHP Biotechnology Award]

2023

  • BrainDTech and Great Product Ventures announce BrainCode, a US Joint Venture with the products and science for providing early and precise diagnostics for precision medicine. [Press release]

2021

  • BrainDTech participates at Bio 2021
  • BrainDTech ranked in Top 20 miRNA startups globally (medicalstartups.com)
  • BrainDTech participates at Venture Summit Virtual Connect (Dec 2021)

2020

  • BrainDTech participates at Bio 2020-Digital partnering meeting
  • BrainDTech participates at Bio Europe 2020-Digital partnering meeting
  • BrainDTech is invited to present at “Biotech-Il Futuro Migliore

2019

  • BrainDTech participates at Bio 2019 partnering meting
  • BrainDTech participates at Bio Europe 2019 partnering meeting

2018

  • BrainDTech participates at Bio Europe 2018 partnering meeting
  • BrainDTech presents at European Biotech Meeting at MIND/Human Technopole, 27/09/2018
  • BrainDTech is invited by the Danish Embassy to present at the Danish-Italian Business Club Meeting 18/12/2018

Main projects

Arché 2020 | MicroCATCH

Early diagnosis, prognosis, and monitoring of neurological disorders from liquid biopsy.

The project is focused on the implementation and pateting of a diagnostic device for liquid biopsy able to isolate microglial microvesicles and to identify disease-specific pattern. The main applications of this technology are early diagnostics, prognosis and follow-up for neurological disorders.

Image

Contact us


Image

BrainDTech S.p.A.

P. IVA: 09593150965
MIND - Via Decumano 41, Palazzina 8
20157 Milano - Italy

Mail: info@braindtech.com

Bio4Dreams Startup Network